Diminished interferon-gamma production in gastric mucosa T lymphocytes after H. pylori eradication in duodenal ulcer patients

Hepatogastroenterology. 1999 May-Jun;46(27):1740-5.

Abstract

Background/aims: Helicobacter pylori (H. pylori) infects an estimated 50% of the world population; however, only a small proportion of individuals develop clinical symptoms of gastritis, peptic ulceration or gastric cancer. The variations in disease presentation may be due to differences in bacterial virulence and/or immune response to the pathogen. In a previous study we reported an increased expression of the IL-2 receptor in duodenal ulcer (DU) patients. The present study examines the expression of IL-2 receptor and intracellular lymphokine production in gastric mucosa infiltrating T lymphocytes in DU patients before and after H. pylori eradication.

Methodology: T lymphocytes were isolated from gastric mucosa biopsies by using mechanical and enzymatic tissue desegregation. Ficoll-purified lymphocytes were incubated with monoclonal antibodies and analyzed by using 4-color flow cytometry analysis for the IL-2 receptor (CD25) and intracellular interferon-gamma (IFN-gamma) and IL-4 expression. Lymphocytes from 24 H. pylori-infected patients with severe gastric mucosa infiltration (G2 and G3 histological type in Sydney classification) were analyzed.

Results: We demonstrated a significant decrease in IL-2 receptor expression on gastric mucosa T cells 3 and 12 months after eradication of H. pylori. We also demonstrated a diminished IFN-gamma production 3 and 12 months after H. pylori eradication.

Conclusions: Our results suggest that cellular immune activation in gastric mucosa is reversibly dependent on the presence of H. pylori.

MeSH terms

  • Amoxicillin / adverse effects
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Drug Therapy, Combination
  • Duodenal Ulcer / drug therapy*
  • Duodenal Ulcer / immunology
  • Duodenal Ulcer / pathology
  • Flow Cytometry
  • Follow-Up Studies
  • Gastric Mucosa / drug effects*
  • Gastric Mucosa / immunology
  • Gastric Mucosa / pathology
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / immunology
  • Helicobacter Infections / pathology
  • Helicobacter pylori / drug effects*
  • Helicobacter pylori / immunology
  • Humans
  • Interferon-gamma / metabolism*
  • Interleukin-4 / analysis
  • Metronidazole / adverse effects
  • Metronidazole / therapeutic use
  • Organometallic Compounds / adverse effects
  • Organometallic Compounds / therapeutic use
  • Receptors, Interleukin-2 / analysis
  • Receptors, Interleukin-2 / drug effects
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • T-Lymphocytes / pathology
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Organometallic Compounds
  • Receptors, Interleukin-2
  • Metronidazole
  • Interleukin-4
  • Amoxicillin
  • Interferon-gamma
  • bismuth tripotassium dicitrate